British pharmaceutical giant AstraZeneca sees net profit leap to USD 10.2 billion in 2025, driven by strong oncology sales and strategic expansion in the US and China.
LONDON: British pharmaceutical giant AstraZeneca reported a 45% surge in net profit for 2025, driven by robust sales of its cancer medicines.
Profit after tax climbed to USD 10.2 billion last year, up from USD 7.0 billion in 2024, the company said in a statement on Tuesday.
Revenue increased by 9% to USD 58.7 billion, boosted significantly by growth in its oncology portfolio.
Chief executive Pascal Soriot said the company saw strong commercial performance across all therapy areas and excellent pipeline delivery in 2025.
“The momentum across our company is continuing in 2026,” he added, with the group targeting annual revenue of USD 80 billion by 2030.
AstraZeneca has been aggressively expanding its presence in its two largest markets, the United States and China.
Last month, it announced a USD 15 billion investment plan in China through 2030 to expand manufacturing and research, coinciding with a visit by UK Prime Minister Keir Starmer to Beijing.
During that trip, it also revealed a deal with Chinese firm CSPC Pharmaceutical to co-develop and market weight-loss injections, a rapidly growing market.
Concurrently, the drugmaker is pivoting strategically towards the United States, aiming for it to constitute half of its global revenue by 2030.
The US market already accounted for 43% of its total revenue in 2025.
Highlighting this focus, AstraZeneca began a direct listing of its shares on the New York Stock Exchange in February to attract more American investors.
The company will maintain its headquarters in the UK and its primary share listing in London.
Facing potential pharmaceutical tariffs from US President Donald Trump, AstraZeneca unveiled plans in July to invest USD 50 billion by 2030 to boost its US manufacturing and research footprint.
The Trump administration also forged a deal with the company for significantly lower drug prices in the United States.
In exchange, the government agreed to a three-year delay on imposing new tariffs on its products.
The pharmaceutical industry remains a key target for President Trump, who has imposed drug tariffs on other countries while demanding companies shift operations to the US.